Corient Private Wealth LP Makes New Investment in Pfizer Inc. $PFE

Corient Private Wealth LP bought a new position in shares of Pfizer Inc. (NYSE:PFE) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 2,945,297 shares of the biopharmaceutical company’s stock, valued at approximately $67,485,000.

Other large investors have also recently bought and sold shares of the company. Handelsbanken Fonder AB lifted its holdings in shares of Pfizer by 10.4% in the 2nd quarter. Handelsbanken Fonder AB now owns 2,462,431 shares of the biopharmaceutical company’s stock valued at $59,295,000 after buying an additional 232,528 shares during the period. Russell Investments Group Ltd. grew its holdings in Pfizer by 15.7% during the second quarter. Russell Investments Group Ltd. now owns 5,482,863 shares of the biopharmaceutical company’s stock worth $132,365,000 after acquiring an additional 745,213 shares during the period. Leuthold Group LLC purchased a new position in Pfizer in the second quarter worth $4,887,000. North Dakota State Investment Board purchased a new position in Pfizer in the fourth quarter worth $5,348,000. Finally, Park National Corp OH lifted its holdings in Pfizer by 332.1% in the second quarter. Park National Corp OH now owns 242,081 shares of the biopharmaceutical company’s stock valued at $5,829,000 after acquiring an additional 186,053 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have commented on PFE. JPMorgan Chase & Co. decreased their target price on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating on the stock in a research report on Wednesday, July 8th. Wall Street Zen raised shares of Pfizer from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. HSBC cut shares of Pfizer from a “buy” rating to a “hold” rating and dropped their target price for the company from $32.00 to $28.00 in a report on Monday, July 6th. Guggenheim decreased their price target on Pfizer from $35.00 to $31.00 and set a “buy” rating on the stock in a research note on Friday, August 7th. Finally, BMO Capital Markets dropped their price objective on Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research note on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $28.28.

Pfizer Price Performance

Shares of NYSE:PFE opened at $28.00 on Friday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. The business’s fifty day moving average price is $25.49 and its two-hundred day moving average price is $26.29. The stock has a market cap of $159.62 billion, a PE ratio of 36.85 and a beta of 0.34. Pfizer Inc. has a one year low of $23.58 and a one year high of $28.75.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. The business had revenue of $15.03 billion during the quarter, compared to analyst estimates of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company’s revenue was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, analysts forecast that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.1%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s payout ratio is 226.32%.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The U.S. Food and Drug Administration approved Pfizer and BioNTech’s XFG-adapted 2026–2027 COVID-19 vaccine. The updated Comirnaty formula is intended for adults 65 and older and younger individuals with qualifying health risks, with shipments beginning immediately. The approval supports Pfizer’s ability to compete in the upcoming respiratory-virus season and could provide seasonal revenue support. Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
• Positive Sentiment: The FDA also approved updated COVID-19 vaccines from Moderna and Novavax-Sanofi, following guidance to target the dominant XFG variant. Pfizer’s immediate distribution and extensive real-world safety record may help preserve its position in the U.S. vaccine market, although demand remains difficult to forecast. US FDA approves updated COVID vaccines for 2026-27 season

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.